



SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplex, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/40

Date: 31st October 2024

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01015

Dear Sir/ Madam,

Ref: Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Sub: Outcome of the Meeting of Board of Directors of the Company held on Thursday, 31st October, 2024

Pursuant to Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we are submitting herewith Unaudited Standalone & Consolidated Financial Results for the half year ended on 30th September, 2024 as approved by the Board of Directors of the Company along-with Auditors' Limited Review Report at its meeting held today.

The meeting of the Board of Directors commenced at 19.30 hours and concluded at 22.00 hours.

Kindly take it on your records.

Thanks & Regards,

For, Sudarshan Pharma Industries Limited

Nirav Shah
Company Secretary & Compliance Officer



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Un-Audited Standalone Financial Results for the Half Year ended 30th September, 2024

(Figures are ₹ in Lakhs) (unless specified otherwise '0' denotes amounts less than ₹ Five Hundred)

Sr. No.	Particulars	Half year ended			Year Ended	
		30-Sep-24	31-Mar-24	30-Sep-23	31-Mar-24	31-Mar-23
		Un-Audited	Ref Note 2	Un-Audited	Audited	Audited
	INCOME					
I	Revenue from operations	22,535.02	23,376.31	23,179.92	46,556.23	46,133.19
II	Other Income	145.64	80.66	194.47	275.14	111.71
III	Total Income (I +II)	22,680.66	23,456.97	23,374.40	46,831.37	46,244.90
	EXPENSES					
IV	(a) Cost of Materials Consumed	26.87	168.06	314.39	482.45	32.27
	(b) Purchase of Stock-in-Trade	21,236.98	21,337.29	21,421.07	42,758.35	45,724.89
	(c) Changes in inventories of finished goods, work-in-progress & Stock-in-Trade	(1,440.79)	(569.62)	(217.84)	(787.46)	(2,662.46)
	(d) Employee Benefit Expenses	211.30	188.85	160.82	349.66	297.51
	(e) Finance Costs	760.34	581.68	321.15	902.84	540.23
	(f) Depreciation and Amortization Expense	65.16	62.11	60.83	122.94	90.71
	(g) Other Expenses	916.50	835.35	657.43	1,492.78	1,271.80
	Total Expenses (IV (a to g))	21,776.36	22,603.71	22,717.84	45,321.56	45,294.96
V	Profit before exceptional and extraordinary items and tax	904.30	853.26	656.55	1,509.81	949.93
	Exceptional Items	116.89	-	-	-	-
VI	Profit before extraordinary items and tax	787.41	853.26	656.55	1,509.81	949.93
	Extraordinary items	-	-	-	-	-
VII	Profit before tax	787.41	853.26	656.55	1,509.81	949.93
VIII	Tax expense:					
	(a) Current tax	194.51	230.29	161.63	391.92	241.98
	(b) Deferred tax (Expense) / Income	1.04	(18.11)	5.44	(12.68)	3.97
	(c) Tax for Earlier Year	-	(4.95)	-	(4.95)	-
	Total Tax Expenses	195.55	207.22	167.07	374.28	245.95
IX	Net Profit/(Loss) for the year from continuing operations	591.86	646.04	489.48	1,135.53	703.98
	Profit / (loss) from discontinuing operations before tax	-	-	-	-	-
	Tax expense of discontinuing operations	-	-	-	-	-
	Net Profit / (loss) from discontinuing operations after tax	-	-	-	-	-
	Net Profit/(Loss) for the year	591.86	646.04	489.48	1,135.53	703.98

(Figures are ₹ in Lakhs) (unless specified otherwise '0' denotes amounts less than ₹ Five Hundred)

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S V, Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

Sr. No.	Particulars	Half year ended			Year Ended	
		30-Sep-24	31-Mar-24	30-Sep-23	31-Mar-24	31-Mar-23
		Un-Audited	Un-Audited	Un-Audited	Audited	Audited
X	Paid up Equity Share Capital (Face Value of Equity Shares Rs.10/- each)	2,406.59	2,406.59	2,406.59	2,406.59	2,406.59
XI	Reserve Excluding Revaluation Reserve	-	-	-	8,754.91	7,691.58
XII	Earning per share (in Rs) from Continuing Operations:					
(i)	Basic EPS	2.46	2.68	2.03	4.72	5.46
(ii)	Diluted EPS	2.46	2.68	2.03	4.72	5.46

For Sudarshan Pharma Industries Limited

Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Assets and Liabilities for the period ended 30th September, 2024

(Figures are ₹ in Lakhs) (unless specified otherwise '0' denotes amounts less than ₹ Five Hundred)

Sr. No	PARTICULARS	30-Sep-24 Un-Audited	31-Mar-24 Audited
I	EQUITY AND LIABILITIES		
1	<u>Shareholder's Funds</u>		
(a)	Share Capital	2,406.59	2,406.59
(b)	Reserves and Surplus	9,346.76	8,754.91
2	<u>Non-Current Liabilities</u>		
(a)	Long-Term Borrowings	933.54	1,049.11
(b)	Other Long Term Liabilities	9.06	8.02
(c)	Deferred Tax Liabilities (Net)	6.38	5.35
3	<u>Current Liabilities</u>		
(a)	Short-Term Borrowings	11,700.23	9,639.89
(b)	Trade Payables		
	-total outstanding dues of MSME	2,498.54	2,372.43
	-total outstanding dues of creditors other than MSME	3,375.71	3,285.97
(c)	Other Current Liabilities	1,060.24	697.78
(d)	Short Term Provisions	445.38	264.44
	Total Equity & Liabilities	31,782.43	28,484.48
II	ASSETS		
1	<u>Non-Current Assets</u>		
(a)	Property, Plant and Equipment's and Intangible assets		
	(i) Property, Plant and Equipment	2,011.91	1,995.83
	(ii) Intangible assets	47.24	61.50
	(iii) Capital Work in Progress	202.29	188.04
		2,261.44	2,245.36
(b)	Non-current investments	3,194.42	1,543.84
(c)	Long term loans and advances	496.87	174.98

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

2	Current Assets		
(a)	Current Investments	150.00	150.00
(b)	Inventories	9,882.76	8,436.55
(c)	Trade receivables	12,782.06	12,308.06
(d)	Cash and cash equivalents	26.87	13.12
(e)	Short Term Loans & Advances	341.89	463.45
(f)	Other Current Assets	2,646.12	3,149.11
	Total Assets	31,782.43	28,484.48

For Sudarshan Pharma Industries Limited

Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Cash flow for the period ended 30th September, 2024

(Figures are ₹ in Lakhs) (unless specified otherwise '0' denotes amounts less than ₹ Five Hundred)

Sr. No	PARTICULARS	30-Sep-24 Un-Audited	31-Mar-24 Audited
A.	Cash Flows From Operating Activities		
	Net Profit before Tax and After Exceptional Items	787.41	1,509.81
	Adjustments for:		
	Exceptional Items	116.89	-
	Depreciation	65.16	122.94
	Interest & Finance charges	760.34	902.84
	Interest Income	(43.20)	(93.36)
	Operating Cash Generated Before Working Capital Changes	1,686.60	2,442.23
	(Increase) / Decrease in Inventory	(1,446.21)	(979.76)
	(Increase)/ Decrease in Trade Receivables	(474.00)	(4,157.13)
	(Increase)/Decrease in Other current assets	386.09	(1,163.47)
	(Increase)/Decrease in Short Term Loans & Advances	121.56	623.44
	Increase/(Decrease) in Short term borrowings	2,060.34	7,509.34
	Increase/(Decrease) in Trade Payables	215.86	(3,530.51)
	Increase/(Decrease) in Other Liabilities	362.46	242.14
	Increase / (Decrease) in Short Term Provisions	21.16	18.73
	Increase / (Decrease) in Other Long Term Liabilities	1.04	2.08
	Net Changes in working capital	1,248.31	(1,435.14)
	Less : Tax	34.74	212.16
	Net Cash Flow from Operating Activities (A)	2,900.16	794.92
B.	Cash Flows From Investing Activities		
	Sale / (Purchase) of Fixed Assets (Net)	(66.99)	(191.52)
	Sale / (Purchase) of Non Current Investments (Net)	(1,650.58)	(299.70)
	(Increase) / Decrease in Current Investments	-	(150.00)
	(Increase) / Decrease in Capital Work in Progress	(14.25)	(186.86)
	Interest Income	43.20	93.36
	Net Cash Generated From Investing Activities (B)	(1,688.62)	(734.72)
C.	Cash Flow From Financing Activities		
	Increase / (Decrease) in Share Capital	-	-
	Dividend Paid	(0.00)	(72.20)
	Proceeds / (Repayment) of Long Term Borrowings	(115.57)	(229.72)
	Decrease (Increase) in Long Term Loans & Advances	(321.89)	(13.41)
	Interest Expenses	(760.34)	(902.84)
	Net Cash from Financing Activities [C]	(1,197.80)	(1,218.17)

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	13.75	(1,157.97)
Opening Balance of Cash & Cash Equivalents	13.12	1,171.09
Closing Balance of Cash & Cash Equivalents	26.87	13.12

For Sudarshan Pharma Industries Limited

Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

NOTES TO STANDALONE FINANCIAL RESULTS:

1. The figures mentioned in the financials are unaudited figures, as recommended in Audit Committee Meeting dated 31st October, 2024 and approved in Meeting of Board of Directors of the Company held on 31st October, 2024. Companies whose shares are listed on SME Platform of any Exchange are exempt from compulsory Adoption of IND AS and hence the Company has prepared the Financial Results as per Indian GAAP specified under Section 133 of the Companies Act, 2013.
2. The figures for the half year ended 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited figures upto to the end of the First half year of the financial year which were subjected to Limited Review by the Statutory Auditors. The management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs. The limited review report of the statutory auditors is being filed with BSE Limited and is also available on the Company's website www.sudarshanpharma.com.
3. The standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The Company is engaged in manufacturing of API, job work manufacturing in Pharmaceuticals Items and traders in chemicals and solvents. The Company is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment as per AS-17 on Segment reporting. The segment wise disclosure requirement of Ind AS 108 on operating segment is not applicable to it.
5. The previous periods' figures have been re-grouped / re-arranged wherever necessary to make it comparable with the current period.
6. The Statutory Auditors have conducted a limited review of the above mentioned half year and year to date results and limited review for the corresponding half year financial results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
7. With regards to disruptions of operations for 3 days at Company's warehouse facility located at Arihant Warehouse at Bhiwandi due to natural calamity i.e. heavy rainfall (water logging) in Maharashtra and partial resumption thereof respectively, appropriate steps were taken to restore normalcy and continued operations. Insurance amount claimed by the Company for the loss / damage is INR 286.97 Lakhs and it has been settled by insurance company at Rs.164.84 lakhs so company has booked loss on account of heavy rainfall (water logging) of Rs. 116.89 lakhs as shown the same under the head of exceptional items in published results.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

8. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40.31 lakhs equivalent to approx. Rs. 918.82 Lakhs along with interest at 5% annually on the adjudged amount until the full payment is made.
9. The Company has formed / acquired the following more subsidiary companies:
 - (i) Formed M/s. Sudarshan Maven Pharma Private Limited on 27th August, 2024 by subscribing to 7,000 equity shares of the Company of Rs.10/- each (Rupees Seventy Thousand only) aggregating to 70% of the paid up equity share capital of the Company. The said Company is involved in the business to manufacture, formulate, process, develop, refine, import, export, wholesale and / or retail trade all kinds of pharmaceuticals, API & intermediates, antibiotics, drugs, medicines, biological, nutraceuticals, healthcare, ayurvedic and dietary supplement products.
 - (ii) Acquired 51% of the paid up equity share capital of M/s. Ishwari Healthcare Private Limited on 14th October, 2024 at a consideration of Rs.2,60,00,000/- (Rupees Two Crores and Sixty Lakhs only). Ishwari Healthcare Private Limited is a progressive & innovative company dedicated to serve world market by providing superior services, user-friendly and state-of-the-art healthcare disposables & devices conforming to international standards at competitive prices. The Company is in the business of providing world-class products to cater the needs of global customers more effectively and efficiently.
10. The Compliance related to IND-AS is not applicable to our company as the company is listed on SME Platform of BSE. ®

For Sudarshan Pharma Industries Limited

Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092.



**Independent Auditor's Review Report on Review of Interim Standalone Financial Results
To The Board of Directors of
Sudarshan Pharma Industries Limited**

We have reviewed the accompanying statement of Unaudited Financial Results of Sudarshan Pharma Industries Limited ('The Company') for the half year ended 30th September 2024 ('the statement'), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel & analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: October 31, 2024



For: NGST & Associates
Chartered Accountants
Firm Reg. No. – 135159W

Twinkal P Jain
Partner

Membership No. 156938
UDIN – 24156938BKEMTZ7033



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com. Website : www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Un-Audited Consolidated Financial Results for the Half Year ended 30th September, 2024

(Figures are Rs. in Lakhs) (unless specified otherwise '0' denotes amounts less than Rs. in Five Hundred)

Sr. No.	Particulars	Half year ended			Year Ended	
		30-Sep-24	31-Mar-24	30-Sep-23	31-Mar-24	31-Mar-23
		Un-audited	Un-Audited	Un-Audited	Audited	Audited
	INCOME					
I	Revenue from operations	22,779.09	23,174.24	23,179.92	46,354.16	46,133.19
II	Other Income	124.71	66.05	194.47	260.52	111.71
III	Total Income (I + II)	22,903.80	23,240.29	23,374.40	46,614.68	46,244.90
	EXPENSES					
IV	(a) Cost of Materials Consumed	365.62	316.97	314.39	631.36	32.27
	(b) Purchase of Stock-in-Trade	21,193.29	20,982.99	21,421.07	42,404.06	45,724.89
	Changes in inventories of finished goods, work-in-progress & Stock-in-Trade	(1,598.80)	(569.62)	(217.84)	(787.46)	(2,662.46)
	(d) Employee Benefit Expenses	227.55	203.26	160.82	364.07	297.51
	(e) Finance Costs	751.01	573.30	321.15	894.45	540.23
	(f) Depreciation and Amortization Expense	110.85	63.61	60.83	124.44	90.71
	(g) Other Expenses	934.90	799.25	661.67	1,460.91	1,272.12
	Total Expenses (IV (a to g))	21,984.42	22,369.75	22,722.09	45,091.84	45,295.28
V	Profit before exceptional and extraordinary items and tax	919.38	870.53	652.31	1,522.84	949.62
	Exceptional Items	116.89	-	-	-	-
VI	Profit before extraordinary items and tax	802.49	870.53	652.31	1,522.84	949.62
	Extraordinary items	-	-	-	-	-
VII	Profit before tax	802.49	870.53	652.31	1,522.84	949.62
VIII	Tax expense:					
	(a) Current tax	196.85	236.84	161.63	398.47	241.98
	(b) Deferred tax (Expense) / Income	13.44	(21.64)	5.44	(16.20)	3.97
	(c) Tax for Earlier Year	-	(4.95)	-	(4.95)	-
	Total Tax Expenses	210.29	210.25	167.07	377.31	245.95
IX	Net Profit/(Loss) for the year from continuing operations	592.20	660.29	485.24	1,145.53	703.67
	Profit / (loss) from discontinuing operations before tax	-	-	-	-	-
	Tax expense of discontinuing operations	-	-	-	-	-
	Net Profit / (loss) from discontinuing operations after tax	-	-	-	-	-
	Profit/(Loss) for the year (before adjustment)	592.20	660.29	485.24	1,145.53	703.67
	Add : Share of Revenue Loss/ (Profit) of Minority Interest	(0.13)	-	-	-	-
	Profit/(Loss) for the year/period	592.33	660.29	485.24	1,145.53	703.67

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai – 400092

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

X	Paid up Equity Share Capital (Face Value of Equity Shares Rs.10/- each	2,406.59	2,406.59	2,406.59	2,406.59	2,406.59
XI	Reserve Excluding Revaluation Reserve	-	-	-	8,764.08	7,690.74
XII	Earning per share (in Rs) from Continuing Operations:					
(i)	Basic EPS	2.46	2.74	2.02	4.76	5.48
(ii)	Diluted EPS	2.46	2.74	2.02	4.76	5.48

For Sudarshan Pharma Industries Limited

Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Consolidated Assets and Liabilities for the period ended 30th September, 2024

(Figures are Rs. in Lakhs) (unless specified otherwise '0' denotes amounts less than Rs. in Five Hundred)

Sr. No	PARTICULARS	30-Sep-24 Un-Audited	31-Mar-24 Audited
I	EQUITY AND LIABILITIES		
1	<u>Shareholder's Funds</u>		
(a)	Share Capital	2,406.59	2,406.59
(b)	Reserves and Surplus	9,356.40	8,764.08
(c)	Minority Interest	0.17	-
2	<u>Non-Current Liabilities</u>		
(a)	Long-Term Borrowings	933.53	1,049.11
(b)	Other Long Term Liabilities	9.95	8.53
(c)	Deferred Tax Liabilities (Net)	15.27	1.83
3	<u>Current Liabilities</u>		
(a)	Short-Term Borrowings	11,486.56	9,434.64
(b)	Trade Payables		
	-total outstanding dues of MSME	2,498.54	2,372.43
	-total outstanding dues of creditors other than MSME	3,797.45	3,299.09
(c)	Other Current Liabilities	1,066.59	702.56
(d)	Short Term Provisions	452.01	273.70
	Total Equity & Liabilities	32,023.06	28,312.55
II	ASSETS		
1	<u>Non-Current Assets</u>		
(a)	Propety, Plant and Equipments and Intangible assets		
(i)	Property, Plant and Equipment	2,069.39	2,052.91
(ii)	Intangible assets	47.24	61.50
(iii)	Capital Work in Progress	202.29	188.04
(iv)	Goodwill	392.19	435.90
		2,711.11	2,738.34
(b)	Non-current investments	2,884.02	1,234.14
(c)	Long term loans and advances	505.12	182.83

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai - 400092.

SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

2	Current Assets		
(a)	Current Investments	150.00	150.00
(b)	Inventories	10,140.39	8,574.14
(c)	Trade receivables	12,925.67	12,254.55
(d)	Cash and cash equivalents	41.69	14.35
(e)	Short Term Loans & Advances	-	-
(f)	Other Current Assets	2,665.06	3,164.19
	Total Assets	32,023.06	28,312.55

For Sudarshan Pharma Industries Limited

Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S V Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Consolidated Cash flow for the period ended 30th September, 2024

(Figures are Rs. in Lakhs) (unless specified otherwise '0' denotes amounts less than Rs. in Five Hundred)

Sr. No	PARTICULARS	30-Sep-24 Un-Audited	31-Mar-24 Audited
A.	Cash Flows From Operating Activities		
	Net Profit before Tax and After Exceptional Items	802.49	1,522.84
	Adjustments for:		
	Exceptional Items	116.89	-
	Depreciation	110.85	124.44
	Interest & Finance charges	751.01	894.45
	Interest Income	(21.49)	(78.75)
	Operating Cash Generated Before Working Capital Changes	1,759.75	2,462.99
	(Increase) / Decrease in Inventory	(1,566.25)	(1,039.75)
	(Increase)/ Decrease in Trade Receivables	(671.12)	(4,096.14)
	(Increase)/Decrease in Other current assets	382.24	(1,169.31)
	(Increase)/Decrease in Short Term Loans & Advances	-	1,086.89
	Increase/(Decrease) in Short term borrowings	2,051.92	6,840.19
	Increase/(Decrease) in Trade Payables	624.47	(3,529.47)
	Increase/(Decrease) in Other Liabilities	364.03	244.83
	Increase / (Decrease) in Short Term Provisions	17.14	14.12
	Increase / (Decrease) in Other Long Term Liabilities	1.42	2.59
	Net Changes in working capital	1,203.84	(1,646.06)
	Less : Tax	37.63	215.44
	Net Cash Flow from Operating Activities (A)	2,925.96	601.49
B.	Cash Flows From Investing Activities		
	Sale / (Purchase) of Fixed Assets (Net)	(69.37)	(191.52)
	Sale / (Purchase) of Non Current Investments (Net)	(1,649.88)	-
	(Increase) / Decrease in Current Investments	-	(150.00)
	(Increase) / Decrease in Capital Work in Progress	(14.25)	(186.86)
	Purchase consideration for acquisition of Subsidiary Company	-	-
	Sale / (Purchase) of Non-current asset	-	-
	Interest Income	21.49	78.75
	Net Cash Generated From Investing Activities (B)	(1,712.00)	(549.34)
C.	Cash Flow From Financing Activities		
	Amount Received from Minority Interest	0.30	-
	Dividend Paid	0.00	(72.20)
	Proceeds / (Repayment) of Long Term Borrowings	(115.57)	(229.72)
	Decrease (Increase) in Long Term Loans & Advances	(320.34)	(13.41)
	Interest Expenses	(751.01)	(894.45)
	Net Cash from Financing Activities [C]	(1,186.63)	(1,209.79)

Regd. Off.: 301, Aura Biplax, Above Kalyan Jewellers, S V Road, Borivali (West), Mumbai – 400092.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	27.34	(1,157.64)
Opening Balance of Cash & Cash Equivalents	14.35	1,171.85
Add: On Acquisition of Subsidiary Company	-	0.15
Closing Balance of Cash & Cash Equivalents	41.69	14.35

For Sudarshan Pharma Industries Limited



Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S V Road, Borivali (West), Mumbai - 400092

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

NOTES TO CONSOLIDATED FINANCIAL RESULTS

1. The figures mentioned in the financials are unaudited figures, as recommended in Audit Committee Meeting dated 31st October, 2024 and approved in Meeting of Board of Directors of the Group held on 31st October, 2024. Companies whose shares are listed on SME Platform of any Exchange are exempt from compulsory Adoption of IND AS and hence the Group has prepared the Financial Results as per Indian GAAP specified under Section 133 of the Companies Act, 2013.
2. The figures for the half year ended 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited figures upto to the end of the First half year of the financial year which were subjected to Limited Review by the Statutory Auditors. The management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs. The limited review report of the statutory auditors is being filed with BSE Limited and is also available on the Company's website www.sudarshanpharma.com.
3. The consolidated financial results of the Group have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The Group is engaged in manufacturing of API, job work manufacturing in Pharmaceuticals Items and traders in chemicals and solvents. The Group is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment as per AS-17 on Segment reporting. The segment wise disclosure requirement of Ind AS 108 on operating segment is not applicable to it.
5. The previous periods' figures have been re-grouped / re-arranged wherever necessary to make it comparable with the current period.
6. The Statutory Auditors have conducted a limited review of the above mentioned half year and year to date results and limited review for the corresponding half year financial results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
7. With regards to disruptions of operations for 3 days at Group's warehouse facility located at Arihant Warehouse at Bhiwandi due to natural calamity i.e. heavy rainfall (water logging) in Maharashtra and partial resumption thereof respectively, appropriate steps were taken to restore normalcy and continued operations. Insurance amount claimed by the group for the loss / damage is INR 286.97 Lakhs and it has been settled by insurance group at Rs.164.84 lakhs so group has booked loss on account of heavy rainfall (water logging) of Rs. 116.89 lakhs as shown the same under the head of exceptional items in published results.



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) **CIN :** L51496MH2008PLC184997

8. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40.31 lakhs equivalent to approx. Rs. 918.82 Lakhs along with interest at 5% annually on the adjudged amount until the full payment is made.
9. The Compliance related to IND-AS is not applicable to our company as the company is listed on SME Platform of BSE.
10. The accounts of the following subsidiaries of the Companies are been considered while preparing consolidated Financial Results / Statements of the Group.
 - Sudarshan Pharma Lifescience Private Limited
 - Lifescience Chemical Private Limited
 - Ratna Lifesciences Private Limited
 - Sudarshan Maven Pharma Private Limited

For Sudarshan Pharma Industries Limited


Hemal Mehta
(Managing Director)
DIN : 02211121



Place : Mumbai
Date : 31st Oct 2024



**Independent Auditor's Review Report on Review of Interim Consolidated Financial Results
To The Board of Directors of Sudarshan Pharma Industries Limited**

We have reviewed the accompanying statement of consolidated unaudited financial results of M/s. Sudarshan Pharma Industries Limited ("the company") and its subsidiary companies (the Holding Company and its subsidiaries collectively referred to as "the Group") for the half ended on 30th September 2024 ("the statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel & analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the results of following entities in so far as they relate to the Consolidated Financial Results;

Subsidiary Companies –

- 1) Sudarshan Pharma Lifescience Private Limited
- 2) Life Science Chemical Private Limited
- 3) Ratna Life Sciences Private Limited
- 4) Sudarshan Maven Pharma Private Limited

Based on our review conducted as above nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For: NGST & Associates
Chartered Accountants
Firm Reg. No. – 135159W

Place: Mumbai
Date: October 31, 2024



Twinkal P Jain
Partner
Membership No. 156938
UDIN – 24156938BKEMUA3210